RAC 0.31% $1.60 race oncology ltd

Industry news, page-967

  1. 2,741 Posts.
    lightbulb Created with Sketch. 3375
    If Dominissini validates Zan as an FTO inhibitor; the market opportunity goes from 'niche aml chemotherapeutic' to 'every cancer subset where fto expression is high and every cancer treatment that upregulates fto expression (almost all of them)'.

    Holders would be better off digesting the magnitude of this potential revelation rather than concerning themselves with overseas listing's.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.